Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter

Coverage

Vitrolife

Vitrolife

Read in Swedish

Change in number of shares and votes in Vitrolife AB (publ)

17:30 / 30 December 2021 Vitrolife Press release

In accordance with the decision at the Extraordinary General Meeting on 20 October 2021, Vitrolife AB has issued a total of 17,251,312 new shares. As of 30 December 2021, following the new issue of shares, the number of shares and votes in Vitrolife AB (publ) amounts to 135,447,190.

Gothenburg, December 30, 2021
VITROLIFE AB (publ)
Thomas Axelsson, CEO

_________________________________________________________________________________________________________________

Vitrolife is an international medical device and genetic services Group. Vitrolife develops, produces and markets products for reproductive health together with services that provide personalised genetic information to improve clinical practices in infertility, women's health and rare diseases. Headquartered in Gothenburg, Sweden, the Group currently employs approximately 1,200 people worldwide. Its products, services and solutions are available in more than 110 markets through a network of subsidiaries and distributors. The Group has a wide-ranging experience in the fertility field with an advanced research capacity. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com.Website: www.vitrolife.com/

Show as PDF

Show original from Cision

Cision

This information was distributed by Cision http://www.cisionwire.se/